WS
ADAP

Wedbush Securities’s Adaptimmune Therapeutics ADAP Stock Holding History

Wedbush Securities’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,889
Closed -$56K – 844
2016
Q4 		$56K Buy
+13,889
New +$66.6K 0.01% 773

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wedbush Securities's ADAP Position: Q1 2017 in Review

Wedbush Securities sold out of Adaptimmune Therapeutics (ADAP) in Q1 2017, closing a stake of 13,889 shares — an estimated $56K sold.

Wedbush Securities first reported a position in ADAP in Q4 2016 and held it in 1 quarter. The position peaked at $56K in Q4 2016. 49 funds tracked by Wall St. Rank hold ADAP as of Q1 2017.

  • Wedbush Securities reported no remaining Adaptimmune Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Wedbush Securities sold 13,889 Adaptimmune Therapeutics shares in Q1 2017, an estimated $56K.
  • Wedbush Securities first reported a position in Adaptimmune Therapeutics in Q4 2016 and held it in 1 quarter.
  • Wedbush Securities's Adaptimmune Therapeutics position peaked at $56K in Q4 2016.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2017.

Based on Wedbush Securities's 13F filing for Q1 2017, filed 5 May 2017.